AIxCrypto Holdings (AIXC) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
9 Sep, 2026Company overview and business model
Principal focus is RoboShare, an on-demand robot-sharing marketplace connecting robot owners with enterprises and institutions for equipment rentals and related services.
Operates an asset-light model, earning platform fees and direct service revenue from third-party-owned robots; does not own any robot equipment.
RoboShare launched in June 2026, with initial commercial activity in Los Angeles and two paid orders completed by August 2026.
Other initiatives, including RWA tokenization, EAI infrastructure, and legacy biotech operations, have been deprioritized or wound down.
The company is using a 90-day validation plan to assess demand, utilization, and unit economics before broader expansion.
Financial performance and metrics
Completed two paid RoboShare orders in August 2026 with aggregate gross order amounts of approximately $5,000; a $33,000 one-year rental order remains unpaid and unconfirmed.
As of August 31, 2026, held digital asset treasury positions valued at approximately $4.82 million, primarily in BTC, ETH, and SOL.
Closed a $41 million PIPE financing in September 2025 and rebranded in November 2025.
Use of proceeds and capital allocation
May receive up to $3.48 million in gross proceeds from the sale of up to 4,044,975 shares under the Purchase Agreement, based on recent VWAP pricing.
Proceeds are intended for working capital and general corporate purposes, with priority on RoboShare development, technology, personnel, fulfillment, logistics, and winding down other initiatives.
The company retains broad discretion over capital allocation and may adjust priorities based on operating results and liquidity.
Latest events from AIxCrypto Holdings
- IPO registers up to 4M shares to fund RoboShare, an early-stage robot-sharing marketplace.AIXC
Registration filing - Offering up to 4,044,975 shares to fund AI and blockchain infrastructure growth, with dilution risk.AIXC
Registration filing - RoboShare launch prioritized as Q2 expenses drop 32%, but net loss and liquidity risks remain.AIXC
Q2 2026 - Net loss narrowed, but severe liquidity and going concern risks persist despite new capital raised.AIXC
Q4 2024 - Raising up to $4M for cancer drug development, with high dilution and Nasdaq delisting risk.AIXC
Registration filing - Clinical-stage cancer drug developer seeks up to $4M via equity offering amid financial risks.AIXC
Registration filing - Cancer therapeutics firm seeks up to $1.8M via share/warrant offering amid high financial risk.AIXC
Registration filing - Liquidity crisis persists as cash runs low, with urgent need for financing to avoid delisting.AIXC
Q1 2024 - Cancer drug developer seeks up to $3.7M via share/warrant offering amid Nasdaq delisting risk.AIXC
Registration filing